Novacyt S.A. (FRA:NYZ)

Market Cap	28.91M -32.8%
Revenue (ttm)	22.69M +39.5%
Net Income	-35.47M
EPS	-0.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.4140
Previous Close	0.3950
Day's Range	0.3845 - 0.4140
52-Week Range	0.3650 - 0.7250
Beta	n/a
RSI	47.89
Earnings Date	Apr 30, 2026

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 234
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NYZ

Financial Performance

In 2024, Novacyt's revenue was 19.63 million, an increase of 84.82% compared to the previous year's 10.62 million. Losses were -41.76 million, 47.6% more than in 2023.

Financial numbers in GBP